Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients.
Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cbc.ca — the content belongs to CBC Health.
